Related Experiment Video
Updated: Jun 7, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Molecular cloning and characterization of a novel esophageal cancer related gene
Yongping Cui1, Meixia Bi, Tao Su
1Department of Chemical Etiology and Carcinogenesis, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, PR China.
Abstract:
We previously identified four novel cDNA fragments related to human esophageal cancer. One of the fragments was named esophageal cancer related gene 2 (ECRG2). We report here the molecular cloning, sequencing, and expression of the ECRG2 gene. The ECRG2 cDNA comprises a 258 bp nucleotide sequence which encodes for 85 amino acids with a predicted molecular weight of 9.2 kDa. Analysis of the protein sequence reveals the presence at the N terminus of a signal peptide followed by 56 amino acids with a significant degree of sequence similarity with the conserved Kazal domain which characterizes the serine protease inhibitor family. Pulse-chase experiments showed that ECRG2 protein was detected in both cell lysates and culture medium, indicating that the ECRG2 protein was extracellularly secreted after the post-translational cleavage. In vitro uPA/plasmin activity analysis showed the secreted ECRG2 protein inhibited the uPA/plasmin activity, indicating that ECRG2 may be a novel serine protease inhibitor. Northern blot analysis revealed the presence of the major band corresponding to a size of 569 kb throughout the fetal skin, thymus, esophagus, brain, lung, heart, stomach, liver, spleen, colon, kidney, testis, muscle, cholecyst tissues and adult esophageal mucosa, brain, thyroid tissue and mouth epithelia. However, ECRG2 gene was significantly down-regulated in primary esophageal cancer tissues. Taken together, these results indicate that ECRG2 is a novel member of the Kazal-type serine protease inhibitor family and may function as a tumor suppressor gene regulating the protease cascades during carcinogenesis and migration/invasion of esophageal cancer.
Insights
Esophageal cancer related gene 2 (ECRG2) is a novel Kazal-type serine protease inhibitor. This gene, found in various tissues, is down-regulated in esophageal cancer, suggesting it acts as a tumor suppressor.
Area of Science:
- Molecular Biology
- Biochemistry
- Oncology
Background:
- Esophageal cancer is a significant health concern with limited therapeutic options.
- Novel genes involved in cancer development require thorough characterization.
- Previous research identified novel cDNA fragments associated with human esophageal cancer.
Purpose of the Study:
- To investigate the molecular cloning, sequencing, and expression of the esophageal cancer related gene 2 (ECRG2).
- To determine the functional role of ECRG2 protein in protease activity and its implications in esophageal carcinogenesis.
Main Methods:
- Molecular cloning and sequencing of ECRG2 cDNA.
- Analysis of ECRG2 protein sequence for functional domains (Kazal domain, signal peptide).
- Pulse-chase experiments to assess protein secretion.
- In vitro assays to evaluate inhibition of urokinase-type plasminogen activator (uPA)/plasmin activity.
- Northern blot analysis to determine tissue-specific gene expression.
Main Results:
- ECRG2 cDNA encodes an 85-amino acid protein with a predicted molecular weight of 9.2 kDa, featuring a Kazal domain.
- ECRG2 protein is extracellularly secreted and inhibits uPA/plasmin activity, identifying it as a potential serine protease inhibitor.
- ECRG2 gene is widely expressed in various fetal and adult tissues.
- ECRG2 gene expression is significantly down-regulated in primary esophageal cancer tissues compared to normal tissues.
Conclusions:
- ECRG2 is a novel Kazal-type serine protease inhibitor.
- ECRG2 may function as a tumor suppressor gene in esophageal cancer.
- The inhibition of protease cascades by ECRG2 is crucial for regulating carcinogenesis and tumor cell migration/invasion.
